Compare Hilton Hotels Corporation Common Stock (HLT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Novartis AG — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.14B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 3.8× Hilton Hotels Corporation Common Stock's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Novartis AG for 82 Days on average.
| HLT | NVS | |
|---|---|---|
Market Cap | $72.14B | $274.00B |
Volume | 862,817 | 1,852,137 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $168.62 |
52-Week Low | $256.96 | $121.80 |
Typical Hold Time | 138 Days | 82 Days |
Enterprise Value | $85.15B | $315.32B |
Dividend Yield | 0.19% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.29, up 0.21% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $12.04B in 2025, with net income of $1.46B and consistent quarterly EPS beats. Recent news highlights upcoming Q3 2026 earnings and positive travel trends for 2027.
Outlook remains positive with a consensus price target of $348.11, though high debt levels and valuation multiples pose risks. Earnings growth and global expansion in Asia present opportunities, but investors should monitor interest expense and competitive pressures in the hospitality sector.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
